Hyderabad-based pharmaceutical major, Dr Reddy's Laboratories Limited, has launched Montelukast sodium oral granules, a generic drug used for the treatment of asthma, allergy and bronchospasm, in the US market.
Dr Reddy's Montelukast sodium oral granules, the bioequivalent generic version of Merck Co’s Singulair oral granules, are available in unit dosage package of 30, the company said in a filing to the BSE on Thursday.
The Singulair oral granules' brand had US sales of approximately $61 million for the most-recent 12 months ending July 2012, according to IMS Health.
Dr Reddy's scrip is currently trading at Rs 1,632.65 on the BSE, up 0.36%, over the previous close of Rs 1,626.80.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app